about
The levels of RAC3 expression are up regulated by TNF in the inflammatory response.The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action.RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis.The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP.CRE-mediated transcriptional activation is involved in cAMP protection of T-cell receptor-induced apoptosis but not in cAMP potentiation of glucocorticoid-mediated programmed cell death.Transrepression of NF-kappaB is not required for glucocorticoid-mediated protection of TNF-alpha-induced apoptosis on fibroblasts.Circadian responses to endotoxin treatment in mice.Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated.Suprachiasmatic astrocytes as an interface for immune-circadian signalling.Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1.Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion proteinSerotonin inhibition of tumor necrosis factor-alpha synthesis by human monocytesLow lymphocyte interferon-gamma production and variable proliferative response in anorexia nervosa patientsRAC-3 is a NF-kappa B coactivatorTNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa BFludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathwayExtract from Aloysia polystachya Induces the Cell Death of Colorectal Cancer Stem CellsThe inflammatory cytokine TNF contributes with RAC3-induced malignant transformation
P50
Q33729031-B0E30C0B-FAD5-414B-8AEF-06796A54E317Q40060512-83801054-D1EC-470D-9A70-392369CBFAA8Q40069750-1995BD38-DABE-4318-B235-3BA7863BB438Q40462575-2761A098-D0D4-4B44-A4DE-8EDA42CFCBF0Q40749841-6F0382D1-1618-4532-8979-440A33FD8666Q40837199-3CFF76CD-0FA2-4F02-A649-AE1027C85FE3Q45264674-B0DC07E5-0376-4629-A0B7-818FB710CC46Q46557320-1964966D-6DCF-433C-9AFE-0C41E04AA8F2Q48428237-70D85FB5-A6A5-4173-A6EB-887F39DEDFDBQ53803000-B01A4590-634A-400E-8E50-53BA73C78F9CQ63648184-32D09CB9-7334-4AA1-BB24-85B943F32E42Q70180862-A13BB0C3-A584-44AD-BA73-DCC07E80159DQ72725263-6DA4A89F-E651-4EB9-8266-9E4C8EB4D091Q73230918-F5F68A99-DBCA-454F-A20B-AF1C85B60E05Q81580785-40F79D30-3ABA-431D-A5BF-8F78932C55B8Q82875854-C86B01F8-E38E-4DBF-8B07-058CEB20B8D2Q90408526-ECCBC676-46A8-4C27-9295-3D1BC1E3CD0EQ90751062-F3269144-5FD9-488D-8CAA-8BE48D7D14D0
P50
description
researcher ORCID ID = 0000-0002-4773-3389
@en
wetenschapper
@nl
name
Mónica A Costas
@ast
Mónica A Costas
@en
Mónica A Costas
@es
Mónica A Costas
@nl
type
label
Mónica A Costas
@ast
Mónica A Costas
@en
Mónica A Costas
@es
Mónica A Costas
@nl
prefLabel
Mónica A Costas
@ast
Mónica A Costas
@en
Mónica A Costas
@es
Mónica A Costas
@nl
P106
P1153
7005238633
P31
P496
0000-0002-4773-3389